

PEXLITH

CERTIFICATE OF ANALYSIS

GLP-2 T

BATCH / LOT

DR100N052226

TESTING DATE

2026-08-04

TESTING LABORATORY

Accumark Labs

Pexlith company branding. Laboratory test data, signatures and verification information retained.



Pexlith

SAMPLE NAME:
SAMPLE CODE:
RECEIVED DATE:
PUBLISHED DATE:

DUAL GIP & GLP-1 RECEPTOR
AGONIST
FBNN-Y7N9
05/29/2026
08/04/2026



DECLARED IDENTITY

Tirzepatide

MATRIX TYPE:

PEPTIDE

SAMPLE NAME:

DUAL GIP & GLP-1 RECEPTOR
AGONIST



123.99 mg
Total Quantity

SAMPLE SIZE:

100.0 mg

LOT CODE:


DR100N052226



99.77%
Total Blend Purity

Sample	Test	Specification	Result	Status
Tirzepatide	IDENTITY	Tirzepatide	Tirzepatide	CONFORMS
Tirzepatide	QUANTITY	MEASURE	123.99 mg	MEASURED
Tirzepatide	PURITY	> 98.0%	99.77%	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:

Anthony Burke PhD
Lab Manager
08/04/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
08/04/2026

ACCUMARKLABS.COM
FBNN-Y7N9
08/04/2026





Pexlith

SAMPLE NAME:
SAMPLE CODE:
RECEIVED DATE:
PUBLISHED DATE:

DUAL GIP & GLP-1 RECEPTOR
AGONIST
FBNN-Y7N9
05/29/2026
08/04/2026

Sample	Test	Specification	Result	Status
Tirzepatide	Endotoxin (LAL)	≤ 5.0 EU/mL	Pass	CONFORMS
Tirzepatide	Rapid Sterility Screening (PCR)	Not Detected	Pass	CONFORMS

PEX-1
PEP-1
TIDES

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
08/04/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
08/04/2026

ACCUMARKLABS.COM
FBNN-Y7N9
08/04/2026

